Fig. 6.
B16-F10-4-1BBL-B7.1-IFNγ/β anticancer vaccine protects LTα−/− mice against tumour challenge and increases % TEM cell population. Vaccinated LTα−/− mice that remained tumour free after initial tumour challenge were boosted twice with the B16-F10-4-1BBL-B7.1-IFNγ/β cell vaccine (n = 3) and re-challenged with B16-F10-B7.1 tumour cells. Control, unvaccinated mice challenged with tumour cells (control + tumour; n = 3) and unvaccinated mice that remained untreated (control; n = 4) were also assessed. Spleens were collected and weighed (a), and then, lymphocytes from spleens (b) and peripheral blood (c) were analysed for CD4+ and CD8+ T-cell populations. CD8+ T-cell populations in spleens (d) and peripheral blood (e) were further analysed for the presence of TEM and TCM CD8+ T-cell subpopulations. The mean ± SEM is presented, and significance levels are denoted by: ★p < 0.05; ★★p < 0.01; ★★★p < 0.005